- Home
- HBT vs CSTL Comparison
HBT vs CSTL Comparison
Compare HBT & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBT
- CSTL
- Stock Information
- Founded
- HBT 1920
- CSTL 2007
- Country
- HBT United States
- CSTL United States
- Employees
- HBT N/A
- CSTL N/A
- Industry
- HBT Major Banks
- CSTL Medical Specialities
- Sector
- HBT Finance
- CSTL Health Care
- Exchange
- HBT Nasdaq
- CSTL Nasdaq
- Market Cap
- HBT 756.5M
- CSTL 848.1M
- IPO Year
- HBT 2019
- CSTL 2019
- Fundamental
- Price
- HBT $22.24
- CSTL $27.39
- Analyst Decision
- HBT Hold
- CSTL Strong Buy
- Analyst Count
- HBT 6
- CSTL 6
- Target Price
- HBT $23.83
- CSTL $39.67
- AVG Volume (30 Days)
- HBT 34.7K
- CSTL 313.3K
- Earning Date
- HBT 01-22-2025
- CSTL 11-04-2024
- Dividend Yield
- HBT 3.31%
- CSTL N/A
- EPS Growth
- HBT 12.67
- CSTL N/A
- EPS
- HBT 2.20
- CSTL 0.21
- Revenue
- HBT $212,336,000.00
- CSTL $311,878,000.00
- Revenue This Year
- HBT N/A
- CSTL $51.36
- Revenue Next Year
- HBT $0.02
- CSTL N/A
- P/E Ratio
- HBT $10.43
- CSTL $132.63
- Revenue Growth
- HBT N/A
- CSTL 62.43
- 52 Week Low
- HBT $17.75
- CSTL $16.97
- 52 Week High
- HBT $25.35
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- HBT 35.62
- CSTL 39.09
- Support Level
- HBT $23.30
- CSTL $27.51
- Resistance Level
- HBT $24.23
- CSTL $32.57
- Average True Range (ATR)
- HBT 0.61
- CSTL 1.55
- MACD
- HBT -0.22
- CSTL -0.23
- Stochastic Oscillator
- HBT 21.33
- CSTL 17.49
About HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.